Effect of immunoglobulin light chains from hemodialysis and continuous ambulatory peritoneal dialysis patients on polymorphonuclear leukocyte functions.
Circulating plasma factors accumulating in the serum of uremic patients have the potential to inhibit essential functions of polymorphonuclear leukocytes (PMNL). As a consequence, these factors can contribute to the increased risk for bacterial infections generally found in uremic patients. Free immunoglobulin light chains that are present in the serum of healthy adults at low levels appear in the serum of uremic patients at significantly higher levels. Therefore, kappa and lambda light chains in their monomeric and dimeric forms were isolated from hemodialysis and continuous ambulatory peritoneal dialysis patients and their potential to inhibit essential PMNL functions in in vitro assays was tested. It was found that all isolates tested were able to inhibit deoxyglucose uptake, a measure for the state of activation of PMNL, as well as chemotaxis. In contrast, free immunoglobulin light chains had no influence on the phagocytotic functions of PMNL. It was concluded that free immunoglobulin light chains are able to act as uremic toxins by interfering with essential PMNL functions and that their serum levels and fate during the treatment of uremic patients should be taken into consideration.
Cohen
G
G
Department of Medicine, University of Vienna, Austria.
Haag-Weber
M
M
Mai
B
B
Deicher
R
R
Hörl
W H
WH
D002633:Chemotaxis / Q000187:drug effects*; D005947:Glucose / Q000378:metabolism; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000009:adverse effects*; D009504:Neutrophils / Q000187:drug effects* / Q000378:metabolism; D010531:Peritoneal Dialysis, Continuous Ambulatory; D010587:Phagocytosis / Q000187:drug effects*; D006435:Renal Dialysis; D012307:Risk Factors; D014511:Uremia / Q000378:metabolism* / Q000628:therapy
D007147:Immunoglobulin Light Chains; D005947:Glucose